LA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU).

加利福尼亚州拉霍亚，2023年10月26日（GLOBE NEWSWIRE）-在纳斯达克全球市场（纳斯达克股票交易所：MNOV）和东京证券交易所标准市场交易的生物制药公司MediciNova，Inc.（代码编号：4875），今天宣布其合作者Genzyme Corporation，赛诺菲的子公司，已经在SAR444836的临床试验中治疗了第一位用于治疗苯丙酮尿症（PKU）的患者。

SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology which is covered under MediciNova’s assignment agreement with Genzyme Corporation. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.

SAR444836是基于腺伴随病毒（AAV）载体技术的苯丙氨酸羟化酶（PAH）替代基因治疗产品，其在MediciNova与Genzyme Corporation的转让协议中涵盖。关于MediciNova MediciNova，Inc。是一家临床阶段的生物制药公司，为炎症，纤维化和神经退行性疾病开发新型小分子疗法的广泛后期管道。

Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS).

基于两种化合物MN-166（ibudilast）和MN-001（tipelukast），具有多种作用机制和强大的安全性，MediciNova在临床开发中有11个项目。MediciNova的主要资产MN-166（ibudilast）目前正处于肌萎缩侧索硬化症（ALS）和退行性颈椎病（DCM）的第3阶段，并已准备好进行性多发性硬化症（MS）的第3阶段。

MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma, Long COVID, and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

MN-166（ibudilast）也正在胶质母细胞瘤，长期新型冠状病毒肺炎和物质依赖的2期临床试验中进行评估。MN-001（tipelukast）在特发性肺纤维化（IPF）的2期临床试验中进行了评估，非酒精性脂肪性肝病（NAFLD）的第二阶段试验正在进行中。MediciNova在确保由政府资助资助的研究者赞助的临床试验方面有着良好的记录。

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor pr.

本新闻稿中非历史性的陈述构成了安全港公关意义内的前瞻性陈述。